JP2020500885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500885A5 JP2020500885A5 JP2019529975A JP2019529975A JP2020500885A5 JP 2020500885 A5 JP2020500885 A5 JP 2020500885A5 JP 2019529975 A JP2019529975 A JP 2019529975A JP 2019529975 A JP2019529975 A JP 2019529975A JP 2020500885 A5 JP2020500885 A5 JP 2020500885A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seldeg
- seq
- target
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023095266A JP7832913B2 (ja) | 2016-12-02 | 2023-06-09 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
| JP2025094049A JP2025131743A (ja) | 2016-12-02 | 2025-06-05 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
| JP2026035146A JP2026097946A (ja) | 2016-12-02 | 2026-03-05 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662429367P | 2016-12-02 | 2016-12-02 | |
| US62/429,367 | 2016-12-02 | ||
| PCT/US2017/064186 WO2018102668A1 (en) | 2016-12-02 | 2017-12-01 | Fusion proteins for selectively depleting antigen-specific antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023095266A Division JP7832913B2 (ja) | 2016-12-02 | 2023-06-09 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500885A JP2020500885A (ja) | 2020-01-16 |
| JP2020500885A5 true JP2020500885A5 (enExample) | 2021-01-21 |
| JP7295799B2 JP7295799B2 (ja) | 2023-06-21 |
Family
ID=62242041
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529975A Active JP7295799B2 (ja) | 2016-12-02 | 2017-12-01 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
| JP2023095266A Active JP7832913B2 (ja) | 2016-12-02 | 2023-06-09 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
| JP2025094049A Pending JP2025131743A (ja) | 2016-12-02 | 2025-06-05 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
| JP2026035146A Pending JP2026097946A (ja) | 2016-12-02 | 2026-03-05 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023095266A Active JP7832913B2 (ja) | 2016-12-02 | 2023-06-09 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
| JP2025094049A Pending JP2025131743A (ja) | 2016-12-02 | 2025-06-05 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
| JP2026035146A Pending JP2026097946A (ja) | 2016-12-02 | 2026-03-05 | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11459396B2 (enExample) |
| EP (1) | EP3548073A4 (enExample) |
| JP (4) | JP7295799B2 (enExample) |
| CN (1) | CN110799210A (enExample) |
| AU (2) | AU2017366674B2 (enExample) |
| CA (1) | CA3045797A1 (enExample) |
| WO (1) | WO2018102668A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020518240A (ja) * | 2017-01-17 | 2020-06-25 | ザ テキサス エー アンド エム ユニバーシティー システム | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
| AU2018318440A1 (en) | 2017-08-15 | 2020-02-13 | Kindred Biosciences, Inc. | IgG Fc variants for veterinary use |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| EP3715375A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of pre-eclampsia |
| EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| TWI922495B (zh) | 2020-09-23 | 2026-04-21 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物 |
| WO2022063879A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| KR20230074775A (ko) | 2020-09-23 | 2023-05-31 | 아블레비아 바이오테크 게엠베하 | 바이러스 벡터의 효능 증가를 위한 화합물 |
| WO2022063887A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for increasing the efficacy of factor viii replacement therapy |
| EP4217402A1 (en) | 2020-09-23 | 2023-08-02 | Ablevia biotech GmbH | Compound for the prevention or treatment of autoantibody-mediated conditions |
| CN116710143A (zh) | 2020-09-24 | 2023-09-05 | 艾柏力维亚生技有限公司 | 用于预防或治疗重症肌无力的化合物 |
| WO2023180502A1 (en) | 2022-03-24 | 2023-09-28 | Ablevia Biotech Gmbh | Compound for increasing efficacy of oncolytic viruses |
| CN119013290A (zh) | 2022-04-13 | 2024-11-22 | Ose免疫疗法公司 | 用于选择性清除抗体的新型分子 |
| AU2023367846A1 (en) * | 2022-10-26 | 2025-05-01 | Amgen Inc. | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases |
| CN120624489B (zh) * | 2025-08-18 | 2025-12-02 | 天津医科大学总医院 | 一种嵌合aqp4抗体受体、caar-t细胞及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7332168B2 (en) | 2000-08-22 | 2008-02-19 | Micromet Ag | Composition for the elimination of autoreactive B-cells |
| AU2002236499A1 (en) | 2000-11-30 | 2002-06-11 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| PT3190128T (pt) * | 2008-09-17 | 2019-02-07 | Xencor Inc | Composições e métodos para tratar distúrbios mediados pela ige |
| EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| WO2012150319A1 (en) * | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| CN106103476B (zh) * | 2013-12-24 | 2020-11-27 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| US20160060358A1 (en) | 2014-08-28 | 2016-03-03 | California Institute Of Technology | Induction of antigen-specific tolerance |
| US20170334962A1 (en) * | 2016-05-19 | 2017-11-23 | Texas A&M University System | FcRn-TARGETED ANTIGEN FUSION PROTEINS |
-
2017
- 2017-12-01 WO PCT/US2017/064186 patent/WO2018102668A1/en not_active Ceased
- 2017-12-01 EP EP17876621.8A patent/EP3548073A4/en active Pending
- 2017-12-01 JP JP2019529975A patent/JP7295799B2/ja active Active
- 2017-12-01 US US16/465,975 patent/US11459396B2/en active Active
- 2017-12-01 CN CN201780084570.5A patent/CN110799210A/zh active Pending
- 2017-12-01 CA CA3045797A patent/CA3045797A1/en active Pending
- 2017-12-01 AU AU2017366674A patent/AU2017366674B2/en active Active
-
2022
- 2022-09-08 US US17/930,545 patent/US12404339B2/en active Active
-
2023
- 2023-06-09 JP JP2023095266A patent/JP7832913B2/ja active Active
-
2025
- 2025-03-25 AU AU2025202131A patent/AU2025202131A1/en active Pending
- 2025-06-05 JP JP2025094049A patent/JP2025131743A/ja active Pending
-
2026
- 2026-03-05 JP JP2026035146A patent/JP2026097946A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404339B2 (en) | Method of depleting target antigen-specific antibody from a patient by administering a fusion protein (Seldeg) for selectively depleting antigen-specific antibodies | |
| JP7832906B2 (ja) | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート | |
| JP2023109939A (ja) | 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン | |
| US10420820B2 (en) | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides | |
| JP2020526503A5 (enExample) | ||
| CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| SI2802606T1 (en) | Improves the transfer of healing molecules through the hematoencephalic barrier | |
| CN116987189A (zh) | 单链可变片段cd3结合蛋白质 | |
| JP2015509097A5 (enExample) | ||
| JP2024507540A5 (enExample) | ||
| JP2024514556A5 (enExample) | ||
| CA2820630A1 (en) | Dimeric molecular complexes with free cysteine residues and conjugates thereof | |
| US10202432B2 (en) | Dual targeting drug carrier and application thereof | |
| JP2024542096A (ja) | 新規タンパク質 | |
| WO2023246911A1 (zh) | 基于t细胞受体的双特异性多肽分子及其用途 | |
| WO2017147820A1 (zh) | 双重标靶药物载体 | |
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2025530261A (ja) | マルタボディを使用する化学療法耐性腫瘍の処置 | |
| WO2026054854A2 (en) | Light chain amyloid fibril antibodies, amyloid fibril and phagocyte targeting bi-specific phagocyte engagers, car-phagocytes, and uses thereof | |
| JP2026513850A (ja) | Ｐｄｇｆｒアルファを発現するがんを治療する方法 | |
| WO2023169524A1 (zh) | 白细胞介素2突变体以及含有其的复合物 | |
| CN118488971A (zh) | 优化的Multabody构建体、组合物和方法 |